Thus, IACS-010759-based therapies could be considered for treatment of AML cases that are resistant to ivosidenib; supporting this, administering ivosidenib and IACS-010759 concurrently in a panel of IDH1-mutant AML patient-derived xenografts (Pdx) has recently been reported to improve responses, relative to ivosidenib alone, for some IDH1-mutant samples40. The gene discussed is IDH1; the disease is acute myeloid leukemia.